Cheng Zi-Jian, Luo Yu-Feng, Zhu Qing-Yun, Wang Yan-Fei, Ren Wen-Yan, Deng Fei-Yan, Bo Lin, Jiang Xi-Yuan, Lei Shu-Feng, Wu Long-Fei
Center for Genetic Epidemiology and Genomics, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China.
Cambridge-Suda Genomic Resource Center, Jiangsu Key Laboratory of Neuropsychiatric Diseases, Medical College of Soochow University, Suzhou, China.
Nutr Diabetes. 2025 Apr 1;15(1):12. doi: 10.1038/s41387-025-00369-8.
Glucosamine is a widely used supplement for treating osteoarthritis and joint pain. New evidence suggests a potential association between glucosamine and type 2 diabetes, inflammation and cardiometabolic risk. We aimed to prospectively evaluate the association of habitual glucosamine use with risk of diabetic microvascular complications based on data from the large-scale nationwide prospective UK Biobank cohort study.
This analysis included 21,171 participants with type 2 diabetes who were free of microvascular complications from the UK Biobank. Incidence of diabetic microvascular complications was ascertained via electronic health records. The Cox proportional hazards model was used to assess the relationship between glucosamine use and the risk of diabetic microvascular complications. Subgroup analyses and sensitivity analyses were performed to explore the potential effect modifications and the robustness of the main findings.
At baseline, 14.5% of the participants reported habitual use of glucosamine supplements. During a median follow-up of 12.3 years, 4399 people developed diabetic microvascular complications, including 2084 cases of incident diabetic nephropathy, 2401 incident diabetic retinopathy, and 831 incident diabetic neuropathy. Glucosamine use was significantly associated with lower risks of composite microvascular complications (hazard ratio (HR) 0.89, 95% CI: 0.81 to 0.97) and diabetic nephropathy (HR 0.87, 95% CI: 0.76 to 0.98) in fully adjusted models. However, there was no significant inverse association between glucosamine use and the risk of diabetic retinopathy (HR 0.94, 95% CI: 0.83 to 1.06) or diabetic neuropathy (HR 0.88, 95% CI: 0.71 to 1.08).
Habitual use of glucosamine supplement was significantly associated with lower risks of composite microvascular complications and diabetic nephropathy but not retinopathy or neuropathy in individuals with type 2 diabetes.
氨基葡萄糖是一种广泛用于治疗骨关节炎和关节疼痛的补充剂。新证据表明氨基葡萄糖与2型糖尿病、炎症和心血管代谢风险之间可能存在关联。我们旨在基于大规模全国性前瞻性英国生物银行队列研究的数据，前瞻性评估习惯性使用氨基葡萄糖与糖尿病微血管并发症风险之间的关联。
该分析纳入了英国生物银行中21171名无微血管并发症的2型糖尿病患者。通过电子健康记录确定糖尿病微血管并发症的发生率。采用Cox比例风险模型评估使用氨基葡萄糖与糖尿病微血管并发症风险之间的关系。进行亚组分析和敏感性分析以探讨潜在的效应修饰和主要发现的稳健性。
在基线时，14.5%的参与者报告习惯性使用氨基葡萄糖补充剂。在中位随访12.3年期间，4399人发生了糖尿病微血管并发症，包括2084例新发糖尿病肾病、2401例新发糖尿病视网膜病变和831例新发糖尿病神经病变。在完全调整模型中，使用氨基葡萄糖与较低的复合微血管并发症风险（风险比（HR）0.89，95%置信区间：0.81至0.97）和糖尿病肾病风险（HR 0.87，95%置信区间：0.76至0.98）显著相关。然而，使用氨基葡萄糖与糖尿病视网膜病变风险（HR 0.94，95%置信区间：0.83至1.06）或糖尿病神经病变风险（HR 0.88，95%置信区间：0.71至1.08）之间没有显著的负相关。
在2型糖尿病患者中，习惯性使用氨基葡萄糖补充剂与较低的复合微血管并发症和糖尿病肾病风险显著相关，但与视网膜病变或神经病变无关。
